Confo Therapeutics Entered into a Research Collaboration with AbCellera for GPCR-Targeting Antibody Discovery
Shots:
- Confo will be eligible to receive up front, milestones, along with royalties on net product sales
- The collaboration focuses to discover of therapeutic Ab candidates targeting two undisclosed GPCR targets. Additionally, the collaboration will use Confo’s ConfoBody technology to stabilize the selected GPCRs in their disease-relevant conformations & then use as antigens to enable Ab discovery and development
- Confo can develop a multi-indication pipeline of drug candidates using the platform and the pharmacologic and biologic insight to improve therapeutic outcomes for patients with severe diseases who do not have access to disease-modifying medications
Ref: Businesswire | Image: Confo Therapeutics
Related News:- Confo Therapeutics Entered into a Global License Agreement with Eli Lilly for CFTX-1554
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
